*Compass Therapeutics Expects FDA Feedback This Qtr on COMPANION-002 Phase 2/3 Data for Tovecimig (DLL4 X VEGF-A Bispecific Antibody) in Patients With Biliary Tract Cancer >CMPX

Dow Jones · 2d ago

Please log in to view news